Background <p>Poly-ADP ribose polymerase inhibitors (PARPi) are well-known to treat tumors that are deficient in homologous recombination (HR) DNA repair. However, PARPi can treat breast cancer gene (BRCA) wild-type tumors, the mechanisms behind which are not fully elucidated. We previously reported that tumor-intrinsic programmed death ligand-1 (PD-L1) signals promote HR, and that genetic tumor PD-L1<sup>KO</sup> impairs HR and sensitizes tumors…
Telmisartan increases olaparib efficacy in homologous recombination proficient tumors by augmenting type I interferon production
Journal for ImmunoTherapy of Cancer | | Murray, C. E., Ontiveros, C. O., Wentworth, J., Blinkiewicz, P., Leung, B., Bai, H., Spicer, N., Holtz, A., Tanner, C., Balasubramanian, A., Li, W., Dray, E., Zhao, W., Curiel, T. J.
Topics: breast-cancer, immunotherapy, research
Read the full article at Journal for ImmunoTherapy of Cancer